For the histology‐agnostic Type IB trial, the assumption that a molecular aberration behaves identically across histologies may not be true, exemplified by BRAF mutation and differences in clinical benefit in melanoma and colorectal cancer with inhibitory BRAF monotherapy. Here, BRAF is linked to melanoma.